{
    "2019-06-13": [
        [
            {
                "time": "2019-06-13",
                "original_text": "After Hours Most Active for Jun 13, 2019: GE, HAL, CZR, PG, LVS, LLY, HPE, AAPL, FLEX, CMCSA, CINF, ZNGA",
                "features": {
                    "keywords": [
                        "active",
                        "GE",
                        "LLY",
                        "AAPL"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance",
                        "technology",
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-06-13",
                "original_text": "Amgen, Biogen, Gilead and Novo Nordisk have ‘very high’ capacity for M&A, says Moody’s",
                "features": {
                    "keywords": [
                        "M&A",
                        "Amgen",
                        "Biogen",
                        "Gilead",
                        "Novo Nordisk"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-06-01",
                "original_text": "3 Top Diabetes Stocks to Watch in June",
                "features": {
                    "keywords": [
                        "diabetes",
                        "stocks",
                        "watch"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-06-13",
                "original_text": "Thursday Sector Laggards: Healthcare, Utilities",
                "features": {
                    "keywords": [
                        "laggards",
                        "healthcare",
                        "utilities"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "utilities"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-06-13",
                "original_text": "NuCana's Biliary Tract Cancer Candidate Gets Orphan Drug Tag",
                "features": {
                    "keywords": [
                        "NuCana",
                        "orphan drug",
                        "cancer"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-06-13",
                "original_text": "Pfizer's (PFE) Xeljanz Effective As Monotherapy in RA Study",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Xeljanz",
                        "RA",
                        "study"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-06-13",
                "original_text": "Eli Lilly Broke Below the 200-Day Average to Change the Narrative to Bearish",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "200-day average",
                        "bearish"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}